Medically reviewed by Dr. Tom Biernacki, DPM
Not sure which one you have? A podiatrist can tell in one visit — book a real appointment time online, 24/7: Howell or Bloomfield Township. Takes about a minute, 24/7.
Board-certified podiatric surgeon | Balance Foot & Ankle, Howell & Bloomfield Township, MI
Last reviewed: May 2026
Cellulitis and erysipelas look nearly identical on clinical examination — but erysipelas is a more superficial dermis infection that responds faster to antibiotics, while cellulitis involves deeper soft tissue and carries a higher risk of necrotizing fasciitis if it spreads. The sharply raised, demarcated border distinguishes erysipelas and predicts the faster response. Call (810) 206-1402 — foot infection evaluation in Michigan.
Cellulitis and erysipelas are both bacterial skin and soft tissue infections of the foot and lower extremity, but they involve different tissue layers, produce distinctive clinical appearances, and have implications for antibiotic choice and depth of infection. Erysipelas is a superficial infection of the dermis and upper subcutaneous lymphatics — it has a sharply demarcated raised border, a bright crimson-red shiny appearance, and is almost always caused by Group A Streptococcus; it responds rapidly to penicillin. Cellulitis is a deeper infection of the lower dermis and subcutaneous fat — it has an irregular, non-raised border, a more muted pink-red color, and is commonly caused by S. aureus in addition to Streptococcus, particularly in diabetic patients, IV drug users, and patients with skin disruption. Both can cause serious complications if untreated, but erysipelas has a greater risk of rapid bacteremia and sepsis due to superficial lymphatic spread, while cellulitis with poorly controlled diabetes or PVD is more likely to progress to deep space infection or necrotizing fasciitis.
Cellulitis vs. Erysipelas: Clinical and Microbiological Comparison
| Feature | Erysipelas | Cellulitis |
|---|---|---|
| Tissue layer involved | Upper dermis and superficial lymphatics; does not extend below dermis | Lower dermis and subcutaneous fat; deeper than erysipelas |
| Border | Sharply demarcated, raised palpable edge — the hallmark feature; clear line between infected and normal skin | Poorly demarcated, ill-defined, flat border; gradually fades into normal-appearing skin |
| Color | Vivid bright red (erythema) with shiny surface; may have salmon-pink hue; classically described as “St. Anthony’s fire” | Pink to dull red; less vivid than erysipelas; more mottled appearance in severe cases |
| Surface texture | Indurated, shiny, smooth, warm surface; “orange-peel” (peau d’orange) texture from dermal lymphatic involvement | Warm, tender, edematous; less shiny than erysipelas; surface may be smooth or slightly irregular |
| Common organisms | Group A Streptococcus (S. pyogenes) in 80-90% of cases; Group C and G Streptococcus occasionally | Group A Streptococcus and S. aureus (including MRSA) together account for most cases; polymicrobial in diabetic and immunocompromised patients |
| Skin entry point | Small break in skin — tinea pedis fissure, toe web maceration, minor trauma; entry point at distance from main lesion (lymphatic spread) | Local skin disruption — wound, abrasion, ulcer, IV site; infection usually at or adjacent to entry point |
| Systemic symptoms | High fever, chills, rigors preceding or concurrent with skin findings (prodrome); lymphangitic streaking common | Fever common but may be lower-grade; systemic symptoms variable; more common in severe or spreading cellulitis |
| Risk factors | Lymphedema; venous insufficiency; tinea pedis (disrupts skin barrier); previous erysipelas (damaged lymphatics); obesity | Diabetes mellitus; peripheral vascular disease; IV drug use; obesity; chronic skin conditions (eczema, psoriasis); immunosuppression |
| Response to antibiotics | Rapid — 48-72 hours marked improvement with penicillin or amoxicillin; rapid lymphatic spread cleared by bactericidal agents | Slower — 3-5 days for visible improvement; MRSA coverage needed in at-risk patients; recurrence more common without addressing predisposing factors |
Antibiotic Selection and Management for Foot Cellulitis and Erysipelas
| Scenario | First-Line Treatment | Alternative | Duration |
|---|---|---|---|
| Erysipelas (outpatient, non-severe) | Amoxicillin 500mg TID oral; or penicillin VK 500mg QID; covers Group A Streptococcus | Cephalexin 500mg QID; clindamycin if penicillin allergy | 5-7 days; extend if slow response |
| Non-purulent cellulitis (outpatient) | Cephalexin 500mg QID or dicloxacillin 500mg QID; covers Streptococcus and MSSA | Clindamycin 300-450mg TID; TMP-SMX if MRSA risk | 5-7 days; mark borders and reassess 48h |
| Purulent cellulitis / abscess (outpatient) | TMP-SMX DS BID (MRSA coverage); incision and drainage if fluctuant | Doxycycline 100mg BID; clindamycin 300-450mg TID | 5-7 days post-drainage |
| Diabetic cellulitis (outpatient, mild) | Amoxicillin-clavulanate 875/125mg BID; broader polymicrobial coverage | Clindamycin + ciprofloxacin; assess for MRSA risk | 7-10 days; reassess at 48-72h |
| Severe cellulitis / erysipelas (IV, inpatient) | Cefazolin 1-2g IV q8h (non-MRSA risk); or vancomycin 15-20mg/kg IV q8-12h (MRSA risk or failure) | Piperacillin-tazobactam for polymicrobial risk; add clindamycin if toxin-producing strains suspected | IV until improving then step-down to oral; 10-14 days total |
| Recurrent erysipelas (prophylaxis) | Penicillin VK 250mg BID or benzathine penicillin 1.2M units IM monthly; for 1-2 years after recurrence | Erythromycin if penicillin allergic; address lymphedema and tinea pedis as root cause | Long-term prophylaxis if 2+ episodes per year |
At Balance Foot & Ankle in Howell and Bloomfield Township, foot cellulitis is evaluated with the SSTI severity classification — outpatient oral antibiotics for Class I-II infections, emergency department referral for Class III-IV — and the border is marked on presentation to objectively track spread or resolution at the 48-hour reassessment. Call (810) 206-1402.
Ready to Get Relief?
Same-day appointments available in Howell & Bloomfield Township, MI
4.9★ | 1,123 Reviews | 3,000+ Surgeries
Or call: (810) 206-1402
Doctor Answer
What is the difference between cellulitis and erysipelas affecting the foot?
Cellulitis is a diffuse bacterial infection of the deep dermis and subcutaneous tissue causing poorly demarcated redness, warmth, and swelling, while erysipelas is a more superficial infection of the upper dermis with sharply defined, raised borders and a characteristic orange-peel texture. Both are treated with antibiotics targeting streptococcal and staphylococcal bacteria, with erysipelas generally responding faster. Dr. Tom Biernacki at Balance Foot & Ankle accurately distinguishes between these infections and prescribes targeted treatment to prevent spread or recurrence.
Dr. Tom Biernacki, DPM is a board-certified foot & ankle surgeon (ABFAS & ABPM) at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has made him one of the most-followed foot & ankle educators on YouTube.
More questions patients ask
What causes cellulitis of the foot?
Common causes: tinea pedis (athlete's foot) providing bacterial entry through cracked or macerated skin, ingrown toenails, minor trauma, diabetic neuropathy allowing unnoticed wounds, and insect bites. Group A Streptococcus and Staphylococcus aureus (including MRSA) are the most common causative organisms in foot cellulitis. Diabetic patients are at higher risk for gram-negative and polymicrobial infections.
When does cellulitis require hospitalization?
Hospitalization and IV antibiotics are indicated for: systemic signs (fever >38.5°C, tachycardia, hypotension), rapidly spreading infection, failure to improve on oral antibiotics within 48–72 hours, suspected deep tissue or necrotizing infection, diabetic patients with any foot infection, and immunocompromised patients. Elevated CRP, WBC, and ESR indicate systemic inflammatory response requiring more aggressive management.
Still have a question about coverage or cost? Book online and we will check your benefits before your visit: Book in Howell · Book in Bloomfield Township. Prefer to talk it through first? Call (810) 206-1402.